secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0000784199-22-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M
--------------------------------------------------------------------------------

- Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.
- Non-GAAP Q4 net loss ($141K) vs income $7.9M; full year non-GAAP net income $4.9M.
- Full year revenue $298.8M (+18%); net loss ($14.8M) narrowed from ($16.7M) in 2020.
- 2022 outlook: constant currency revenue growth 9-11%; GAAP revenue $319-325M with $6M FX headwind.
- FDA approved AMDS trial start; PMA filed for PerClot US approval; PROACT trials progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/0000784199-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419922000034/aort-20220217x8k.htm
  HTML page:      https://secwatch.observer/filing/0000784199-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer